H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Portage Biotech to $9 from $21 and keeps a Buy rating on the shares post the fiscal 2023 results. The firm took into account higher operating expenses moving forward, an equity raise by end-2023, and the number of clinical catalysts coming over the next 18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRTG:
- Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
- Portage Biotech doses first patient in Phase 1a trial of PORT-6
- Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
- Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting